title: BMA 031 effectively reverses steroid-resistant rejection in renal transplants.
authors.affiliation: Surgical Department B, Rikshospitalet, Oslo, Norway.
authors.forename: P F
authors.initials: PF
authors.lastname: Pfeffer
authors.forename: A
authors.initials: A
authors.lastname: Jakobsen
authors.forename: D
authors.initials: D
authors.lastname: Albrechtsen
authors.forename: G
authors.initials: G
authors.lastname: Sødal
authors.forename: I
authors.initials: I
authors.lastname: Brekke
authors.forename: O
authors.initials: O
authors.lastname: Bentdal
authors.forename: T
authors.initials: T
authors.lastname: Leivestad
authors.forename: P
authors.initials: P
authors.lastname: Fauchald
authors.forename: A
authors.initials: A
authors.lastname: Flatmark
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D006084:Graft Rejection; D006085:Graft Survival; D006801:Humans; D016030:Kidney Transplantation / Q000276:immunology*; D007958:Leukocyte Count; D009894:Opportunistic Infections / Q000150:complications; D013256:Steroids / Q000627:therapeutic use; D013601:T-Lymphocytes / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D013256:Steroids